4-Benzyl-1-piperidin-3-ylmethyl-piperidine | 896053-81-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Benzyl-1-piperidin-3-ylmethyl-piperidine
• 英文别名: 4-Benzyl-1-(piperidin-3-ylmethyl)piperidine
• CAS: 896053-81-9
• 化学式: C₁₈H₂₈N₂
• 分子量: 272.434
• InChiKey: ZLFCILDRNPMXIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-甲氧基苯异氰酸 、 4-Benzyl-1-piperidin-3-ylmethyl-piperidine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 (+/-)-N-(3-methoxyphenyl)-3-[[4-(phenylmethyl)-1-piperidinyl]methyl]-1-piperidinecarboxamide
  参考文献：
  名称：

  CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure–activity relationships

  摘要：

  CCR3 antagonist leads with IC50 values in the muM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC50 values for CCR3. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00206-8
• 作为产物：
  描述：

  3-哌啶甲醇 在 盐酸 、 N-甲基吲哚酮 、 四丙基高钌酸铵 、 3 A molecular sieve 、 三乙酰氧基硼氢化钠 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 4-Benzyl-1-piperidin-3-ylmethyl-piperidine
  参考文献：
  名称：

  CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure–activity relationships

  摘要：

  CCR3 antagonist leads with IC50 values in the muM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC50 values for CCR3. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00206-8

文献信息

• CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure–activity relationships
  作者：Dean A Wacker、Joseph B Santella, III、Daniel S Gardner、Jeffrey G Varnes、Melissa Estrella、George V DeLucca、Soo S Ko、Keiichi Tanabe、Paul S Watson、Patricia K Welch、Maryanne Covington、Nicole C Stowell、Eric A Wadman、Paul Davies、Kimberly A Solomon、Robert C Newton、George L Trainor、Steven M Friedman、Carl P Decicco、John V Duncia

  DOI：10.1016/s0960-894x(02)00206-8

  日期：2002.7

  CCR3 antagonist leads with IC50 values in the muM range were converted into low nM binding compounds that displayed in vitro inhibition of human eosinophil chemotaxis induced by human eotaxin. In particular, 4-benzylpiperidin-1-yl-n-propylureas and erythro-3-(4-benzyl-2-(alpha-hydroxyalkyl)piperidin-1-yl)-n-propylureas (obtained via Beak reaction of N-BOC-4-benzylpiperidine) exhibited single digit nanomolar IC50 values for CCR3. (C) 2002 Published by Elsevier Science Ltd.